Andrea Casadei Gardini, Associate Professor at Vita-Salute San Raffaele University, shared a post on LinkedIn:
“New Publication in Targeted Oncology
I’m proud to share, and especially proud to present, this new article from our group, with Silvia Camera as first author, reflecting an outstanding team effort.
Our international study evaluated the prognostic impact of metastatic sites in patients with advanced biliary tract cancer (BTC) treated with cisplatin, gemcitabine, and durvalumab (CGD).
This real-world analysis included 666 patients and explored whether the number or location of metastatic sites influences outcomes in the era of chemoimmunotherapy.
Key Findings:
• No specific metastatic site independently impacted overall survival (OS) in multivariable analysis.
• Patients with 1–2 metastatic sites showed longer OS and PFS compared with those with 3–5 sites in univariable analysis; however, this association was not confirmed after adjustment.
• Changes in metastatic pattern at progression did not significantly affect post-progression survival (OS2).
Why This Matters
Historically, metastatic burden and distribution have been considered important prognostic factors in BTC. Our findings suggest that in patients treated with CGD, these traditional negative prognostic indicators may be attenuated.
This study contributes to a better understanding of prognostic stratification in the immunochemotherapy setting and may have implications for patient counseling, trial design, and clinical decision-making.
Grateful to all collaborators who made this possible.”
Title: Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab
Authors: Silvia Camera, Lorenzo Fornaro, Margherita Rimini, Mara Persano, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Federico Rossari, Tomoyuki Satake, Frederik Peeters, Francesca Salani, Silvia Bozzarelli, Salvatore Corallo, Jessica Lucchetti, Jin Won Kim, Oluseyi Abidoye, Ilario Giovanni Rapposelli, Chiara Gallio, Stefano Tamberi, Fabian Finkelmeier, Guido Giordano, Pircher Chiara, Hong Jae Chon, Chiara Braconi, Aitzaz Qaisar, Alessandro Pastorino, Florian Castet, Emiliano Tamburini, Changhoon Yoo, Alessandro Parisi, Anna Diana, Mario Scartozzi, Gerald W. Prager, Antonio Avallone, Marta Schirripa, Il Hwan Kim, Lukas Perkhofer, Ester Oneda, Monica Verrico, Nuno Couto, Jorge Adeva, Stephen L. Chan, Gian Paolo Spinelli, Nicola Personeni, Ingrid Garajova, Maria Grazia Rodriquenz, Silvana Leo, Cecilia Melo Alvim, Ricardo Roque, Giovanni Farinea, Virginia Genovesi, Antonio De Rosa, Daniele Lavacchi, Federica Lo Prinzi, Laura Passeri, Michele Ferrara, Silvia Foti, Masafumi Ikeda, Jeroen Dekervel, Monica Niger, Rita Balsano, Giuseppe Tonini, Minsu Kang, Giulia Tesini, Luca Esposito, Chiara Casadio, Vera Himmelsbach, Matteo Landriscina, Selma Ahcene Djaballah, Tanios Bekaii-Saab, Gianluca Masi, Arndt Vogel, Sara Lonardi, Caterina Vivaldi, Lorenza Rimassa, Andrea Casadei-Gardini
Other articles on Biliary Tract Cancer on OncoDaily.